StockNews.com assumed coverage on shares of Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) in a report published on Wednesday. The firm issued a sell rating on the biotechnology company’s stock. Several other research firms also recently weighed in on CNCE. JMP Securities downgraded Concert Pharmaceuticals to a market perform rating in a research note on Thursday, […]